Close Menu

CPTAC

Myriad RBM is collaborating with researchers at the Max Planck Institute of Biochemistry and the Bavarian Red Cross Blood Donor BioBank to identify protein biomarkers for the early detection of colon cancer.

The National Cancer Institute's Clinical Proteomic Technologies for Cancer Initiative this week issued a request for targets for monoclonal antibody production and characterization as part of its Antibody Characterization Program.

This story originally ran on Oct. 6

By Adam Bonislawski
Theranostics Health has licensed a new fixative developed by researchers at George Mason University that could significantly improve the quality of tissue samples available to proteomic researchers.

This story originally ran on Aug. 22 and has been updated to include comments from a participant.
By Adam Bonislawski

BGI, which, according to an official, generated roughly $6.2 million in proteomics revenue last year, plans to buy around 15 new high-resolution machines and 30 to 40 triple quadrupoles as part of its efforts to expand into the clinical proteomics and pharma markets.

The company, called SISCAPA Assay Technologies, will offer assay development to pharmas and CROs and has tapped antibody firm Epitomics to produce reagents for the system and sell SISCAPA kits. So far, the company has licensed the technology to Pfizer for internal use.

Pages

Nebula Genomics will be auctioning George Church's genome as a nonfungible token, according to The Scientist.

Anthony Gregg, the outgoing president of the American College of Medical Genetics and Genomics, has resigned after using racially insensitive language. 

Facebook has developed an artificial intelligence approach to predict how drugs interact in cells, New Scientist reports.

In PNAS this week: adaptations among high-altitude Mycobacterium tuberculosis, response of multiple myeloma cells to chemotherapy-induced stress, and more.